A Roman Timber Bridge at Aldwincle, Northamptonshire

Autor: Jackson, D. A., Ambrose, T. M., Sunter, N. J., Woods, P. J., Ilsley, G. V., Anderson, F. W., Biek, L., Evans, John G., Bayley, Justin, Harcourt, R. A.

Publikováno v: Britannia, 1976 Jan 01. 7, 39-72.

Externí odkaz: https://www.jstor.org/stable/525762

c-MYC is a radiosensitive locus in human breast cells

Autor: Wade, M A, Sunter, N J, Fordham, S E, Long, A, Masic, D, Russell, L J, Harrison, C J, Rand, V, Elstob, C, Bown, N, Rowe, D, Lowe, C, Cuthbert, G, Bennett, S, Crosier, S, Bacon, C M, Onel, K, Scott, K, Scott, D, Travis, L B, May, F E B, Allan, J M

Publikováno v: Oncogene

Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e50a319dc0806b198f91c32c0e64406b
http://europepmc.org/articles/PMC4391966

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Autor: Lin WY; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Fordham SE; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Sunter N; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Elstob C; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Rahman T; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Willmore E; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Shepherd C; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Strathdee G; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Mainou-Fowler T; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Piddock R; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Mearns H; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Barrow T; Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK., Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK., Marr H; Department of Haematology, Freeman Hospital, Newcastle upon Tyne, UK., Wallis J; Department of Haematology, Freeman Hospital, Newcastle upon Tyne, UK., Summerfield G; Queen Elizabeth Hospital, Gateshead, UK., Marshall S; City Hospitals Sunderland NHS Trust, Sunderland, UK., Pettitt A; University of Liverpool, Liverpool, UK., Pepper C; Brighton and Sussex Medical School, University of Sussex, Brighton, UK., Fegan C; Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Forconi F; Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton, UK., Dyer MJS; The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK., Jayne S; The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK., Sellors A; The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK., Schuh A; University of Oxford, Oxford, UK., Robbe P; University of Oxford, Oxford, UK., Oscier D; Royal Bournemouth Hospital, Bournemouth, UK., Bailey J; Hull University Teaching Hospital NHS Trust, Hull, UK., Rais S; Hull University Teaching Hospital NHS Trust, Hull, UK., Bentley A; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, UK., Cawkwell L; University of Hull, Hull, UK., Evans P; Haematological Malignancy Diagnostic Service Laboratory, St James' Institute of Oncology, Leeds, UK., Hillmen P; Section of Experimental Haematology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK., Pratt G; University of Birmingham, Birmingham, UK., Allsup DJ; Hull University Teaching Hospital NHS Trust, Hull, UK. hycda1@hyms.ac.uk.; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, UK. hycda1@hyms.ac.uk., Allan JM; Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. james.allan@newcastle.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2021 Jan 28; Vol. 12 (1), pp. 665. Date of Electronic Publication: 2021 Jan 28.

A comparative study of the capacity of mesenchymal stromal cell lines to form spheroids.

Autor: Deynoux M; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France., Sunter N; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France., Ducrocq E; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France., Dakik H; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France., Guibon R; Anatomie et cytologie pathologique, CHRU de Tours, Tours, France.; INSERM UMR1069, Nutrition, Croissance et Cancer, Université de Tours, Tours, France., Burlaud-Gaillard J; Plateforme IBiSA de Microscopie Electronique, Université et CHRU de Tours, Tours, France.; INSERM U1259 MAVIVH, Université et CHRU de Tours, Tours, France., Brisson L; INSERM UMR1069, Nutrition, Croissance et Cancer, Université de Tours, Tours, France., Rouleux-Bonnin F; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France., le Nail LR; Service de Chirurgie orthopédique, CHU Tours, Tours, France., Hérault O; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France.; Service d'hématologie biologique, CHRU de Tours, Tours, France., Domenech J; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France.; Service d'hématologie biologique, CHRU de Tours, Tours, France., Roingeard P; Plateforme IBiSA de Microscopie Electronique, Université et CHRU de Tours, Tours, France.; INSERM U1259 MAVIVH, Université et CHRU de Tours, Tours, France., Fromont G; Anatomie et cytologie pathologique, CHRU de Tours, Tours, France.; INSERM UMR1069, Nutrition, Croissance et Cancer, Université de Tours, Tours, France., Mazurier F; EA 7501 GICC, CNRS ERL 7001 LNOx, Université de Tours, Tours, France.

Publikováno v: PloS one [PLoS One] 2020 Jun 02; Vol. 15 (6), pp. e0225485. Date of Electronic Publication: 2020 Jun 02 (Print Publication: 2020).

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Autor: Jamieson D; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Sunter N; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Muro S; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Pouché L; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Cresti N; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Northern Centre for Cancer Care, Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK., Lee J; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Sludden J; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Griffin MJ; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Allan JM; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Verrill MW; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Northern Centre for Cancer Care, Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK., Boddy AV; Faculty of Pharmacy, Pharmacy and Bank Building (A15), University of Sydney, Science Road, NSW 2006, Australia. Electronic address: alan.boddy@sydney.edu.au.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Jan; Vol. 71, pp. 15-24. Date of Electronic Publication: 2016 Dec 08.